Do you want to read an article? Please log in or register.
Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Wallace ND, Xie J, Alexander M, Ball D, Hegi-Johnson F, Plumridge N, Siva S, Shaw M, Harden S, John T, Solomon B, Irving L, Duffy M, Officer A, MacManus M
doi: 10.1016/j.cllc.2025.02.010
RECOMMENDED
Lung Cancer
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Thorac Oncol
Kilickap S, Baramidze A, Sezer A, Özgüroğlu M, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang HG, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, Li Y, Zhu C, Kaul M, Perez J, Seebach F, Lowy I, Pouliot JF, Kim E, Magnan H
doi: 10.1016/j.jtho.2025.03.033
RECOMMENDED
Lung Cancer
Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Research Consortium Study BTCRC LUN 16-081
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Wei CX, Althouse SK, Mamdani H, Hanna NH, Durm GA
doi: 10.1016/j.cllc.2024.12.007
Lung Cancer
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
J Clin Med
Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, Karner J, Gruber G, Stana M, Minasch D, Kirchhammer K, Steffal C, Stranzl H, Moosbrugger R, Feurstein P, Dieckmann K, Zehentmayr F, ALLSTAR Group
doi: 10.3390/jcm14030945
RECOMMENDED
Lung Cancer
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Barrichello APC, Elkrief A, Ricciuti B, Ganta T, Marron TU, Wang X, Lotter W, Lindsay J, Santo V, Cortellini A, Sharma B, Felt K, Pfaff K, Lamberti G, Pecci F, Federico AD, Makarem M, Gandhi MM, Nguyen T, Haradon D, Vaz VR, Johnson BE, Debnath N, Wang Y, Kuang AG, Saeed A, Radford M, Lovly CM, Nebhan CA, Pinato DJ, Rodig SJ, Schoenfeld AJ, Awad MM, Alessi JV, Naqash AR
doi: 10.1016/j.cllc.2025.01.014
Lung Cancer
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Lung Cancer (Auckl)
Luo FX, Arter Z, Ou SI, Nagasaka M
doi: 10.2147/LCTT.S520833
Lung Cancer
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study
Clin Lung Cancer
Koster KL, Yohasenan S, Pakmak AS, Mark M, Metaxas Y, Lips C, Hitz F, Leskow P, Ludwig C, Putora PM, Glatzer M, Schneider T, Caviezel C, Mader T, Mousavi M, Blum M, Früh M, Joerger M
doi: 10.1016/j.cllc.2025.05.010
RECOMMENDED
Lung Cancer
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A
doi: 10.1016/j.lungcan.2024.108059
Lung Cancer
Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1-Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
Clin Lung Cancer
Peruzzo N, Lenz G, Akhiwu T, Bilalaga M, Gaddipati GN, Müller NLF, Zarpellon L, Venero F, Corassa M, Cardona AF, Reuss JE, Pellini B
doi: 10.1016/j.cllc.2025.04.006